Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Request metadata listed "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 1998
Status: Development Stage Enterprise
Operations: The Company is engaged in research, development, and licensing of biomedical technologies, specifically the Multi-Dose Solution Inhaler (MSI) and various HIV/AIDS technologies. It has generated minimal operating revenue and relies on equity and debt offerings to fund operations.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 | Inception to Mar 31, 1998 |
|---|---|---|---|
| Total Revenue | $953 | $18,225 | $1,464,780 |
| Net Loss | $(2,263,048) | $(2,668,088) | $(38,340,838) |
| Net Loss (Attributable to Common) | $(2,286,948) | $(2,668,088) | $(38,444,238) |
| Loss Per Share (Basic) | $(0.17) | $(0.23) | $(7.48) |
| Cash and Equivalents (End of Period) | $7,876 | $3,027,503 | N/A |
| Net Cash Used (Operating/Dev) | $(450,092) | $(2,156,954) | $(30,648,542) |
| Total Current Liabilities | $3,079,336 | N/A | N/A |
| Convertible Debentures | $882,000 | N/A | N/A |
| Preferred Stock (Cumulative) | $1,000,479 | N/A | N/A |
Material Changes vs. Prior Period
- Liquidity Crisis: Cash and cash equivalents plummeted from $393,608 at December 31, 1997, to $7,876 at March 31, 1998, a decrease of approximately 98%.
- Expense Reduction: Total operating expenses decreased to $2,264,001 in Q1 1998 from $2,686,313 in Q1 1997. This $422,000 reduction was driven by lower R&D spending ($1.4M decrease) and G&A ($130k decrease), partially offset by a $1.1M expense recognized for a Siemens A.G. license payment due in January 1998.
- Revenue Decline: Interest income dropped to $953 from $18,225 due to reduced cash invested in short-term instruments. No sub-license revenue was recognized in the quarter.
- Debt and Equity Structure: The Company issued 3,093,223 shares of common stock during the quarter via conversion of Series A Preferred Stock and 6% Convertible Debentures.
Outlook, Risks, and Subsequent Events
Management Commentary & Guidance:
- The Company anticipates incurring approximately $2.3 million in additional funding over the next 12 months for clinical research and the final Siemens payment.
- Management believes the ability to continue as a going concern through December 1998 is dependent on obtaining additional financing.
- Committed and anticipated R&D funding after March 31, 1998, is estimated at approximately $16,000,000, primarily for the MSI project.
- Zambon Agreement: On April 15, 1998, the Company entered an option agreement with Zambon Group SpA for a sub-license of the MSI respiratory system. Zambon paid a $650,000 option fee in equity and agreed to fund remaining development costs for respiratory products.
- Series B Offering: On April 15, 1998, the Company issued 1,250 shares of Series B Preferred Stock for $1.25 million. Proceeds were used to pay the overdue DM 2.0 million ($1.1M) Siemens license fee.
- Listing Status: The Company continues to fail to meet certain American Stock Exchange (AMEX) continued listing guidelines.
- Going Concern: Significant doubt exists regarding the Company's ability to meet obligations without additional financing.
- Licensing Default: Failure to make payments to licensors (e.g., Siemens) could result in forfeiture of technology rights.
- Development Risk: No assurance that products will be successfully developed, approved by regulators, or commercialized.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.9 million raised in April 1998 (Zambon fee + Series B) against the $16 million estimated future R&D commitment.
- Siemens Payment: Confirm the status of the DM 2.0 million payment to Siemens A.G. and ensure no further penalties or defaults exist.
- Zambon Definitive Agreement: Monitor the negotiation of the definitive sub-licensing agreement with Zambon, as the $650k fee and funding obligations are contingent on this.
- AMEX Listing: Assess the risk of delisting from the American Stock Exchange and its impact on stock liquidity.
- Preferred Stock Redemption: Review the terms of the Series B Preferred Stock, which must be redeemed upon conclusion of the Zambon sub-license or other financing.